Serina Therapeutics, Inc.
SER
$5.70
-$0.15-2.56%
AMEX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -98.22% | 2,454.21% | 2,368.48% | 741.99% | 433.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.22% | 2,454.21% | 2,368.48% | 741.99% | 433.05% |
| Cost of Revenue | 213.23% | 248.60% | 168.75% | 102.31% | 51.80% |
| Gross Profit | -1,070.46% | -78.63% | 27.82% | 102.85% | 177.93% |
| SG&A Expenses | 255.03% | 175.90% | 162.15% | 80.98% | 78.09% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 233.72% | 205.86% | 165.20% | 91.36% | 63.63% |
| Operating Income | -917.78% | -137.53% | -78.31% | -4.19% | 32.61% |
| Income Before Tax | -312.70% | -304.55% | -689.44% | -3,471.56% | 296.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -312.70% | -304.55% | -689.44% | -3,471.56% | 296.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.44% | -303.06% | -687.18% | -3,471.56% | 296.45% |
| EBIT | -917.78% | -137.53% | -78.31% | -4.19% | 32.61% |
| EBITDA | -967.92% | -139.90% | -77.44% | -2.76% | 34.81% |
| EPS Basic | -319.26% | -351.81% | -749.90% | -2,308.42% | 289.76% |
| Normalized Basic EPS | -470.20% | 2.05% | -56.29% | -139.75% | 63.07% |
| EPS Diluted | -823.33% | -1,853.13% | -1,486.91% | -574.39% | 155.58% |
| Normalized Diluted EPS | -4,311.33% | -252.00% | -227.27% | -214.17% | 94.97% |
| Average Basic Shares Outstanding | 332.74% | 160.15% | 84.32% | 11.18% | 4.21% |
| Average Diluted Shares Outstanding | 39.17% | 18.36% | 34.48% | 63.74% | 253.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |